ImmunoGraft® platform for the evaluation of Immuno-Oncology agents in PDX tumors models

被引：0
|
作者：
Cerna, David
Ciznadija, Daniel
Verma, Bhavna
Sidransky, David
Izumchenko, Evgeny
Davies, Angela
Mancini, Maria
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1648
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1648
引用
收藏
页数：2
相关论文
共 50 条
  • [41] In vitro killing assays for evaluation of immuno-oncology drug candidates
    Arnold, Johan
    Janss, Thibaut J.
    Lefevre, Simon
    Vlaming, Martijn
    Boelen, Ellen
    Pattijn, Sofie
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Development and validation of a phenotypic screening platform for the identification of novel immuno-oncology targets
    Rabolli, Virginie
    Martini, Murielle
    Scoumanne, Ariane
    Letellier, Marie-Claire
    Crosignani, Stefano
    Queva, Christophe
    Detheux, Michel
    Swiercz, Jakub M.
    Cauwenberghs, Sandra
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [43] Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immuno-oncology and translational research
    Alcaniz, Joshua
    Winkler, Lars
    Stecklum, Maria
    Wieland, Hagen
    Siegert, Antje
    Becker, Michael
    Brzezicha, Bernadette
    Walther, Wolfgang
    Hoffmann, Jens
    CANCER RESEARCH, 2023, 83 (07)
  • [44] Systemic and local bone metastasis models for immuno-oncology drug development
    Kahkonen, Tiina E.
    Suominen, Mari I.
    Maki-Jouppila, Jenni H.
    Halleen, Jussi M.
    Scholz, Arne
    Bernoulli, Jenni
    CANCER RESEARCH, 2019, 79 (13)
  • [45] New patient derived lymphoma xenograft (PDX) panel for drug development, immuno-oncology and translational research
    Brzezicha, B.
    Becker, M.
    Stecklum, M.
    Conrad, T.
    Janz, M.
    Bittner, A.
    Schmitt, C. A.
    Hoffmann, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S41 - S41
  • [46] Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
    Maulana, Tengku Ibrahim
    Kromidas, Elena
    Wallstabe, Lars
    Cipriano, Madalena
    Alb, Miriam
    Zaupa, Cecile
    Hudecek, Michael
    Fogal, Birgit
    Loskill, Peter
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 173 : 281 - 305
  • [47] Preclinical tumor models in humanized mice for translational immuno-oncology research
    Stecklum, Maria
    Wulf-Goldenberg, Annika
    Paterka, Magdalena
    Brzezicha, Bernadette
    Fichtner, Iduna
    Hoffmann, Jens
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [48] How humanized mouse models could be useful for immuno-oncology research
    Mirjolet, Jean-Francois
    Caradec, Josselin
    Duchamp, Oliver
    Bichat, Francis
    France, Damien
    Mignard, Caroline
    Viviani, Fabrice
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents
    Zhang, Yong
    Zhao, Yufen
    Tebben, Andrew J.
    Sheriff, Steven
    Ruzanov, Max
    Fereshteh, Mark P.
    Fan, Yi
    Lippy, Jonathan
    Swanson, Jesse
    Ho, Ching-Ping
    Wautlet, Barri S.
    Rose, Anne
    Parrish, Karen
    Yang, Zheng
    Donnell, Andrew F.
    Zhang, Liping
    Fink, Brian E.
    Vite, Gregory D.
    Augustine-Rauch, Karen
    Fargnoli, Joseph
    Borzilleri, Robert M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (11): : 1117 - 1122
  • [50] Immuno-oncology (IO) drug conjugate concentrates at cells and tumors and enhances survival
    Kaulagari, Sridhar Reddy
    Doligalski, Michael
    Cohen, Allison
    Zheng, Hong
    Estrella, Veronica
    Beg, Amer
    Morse, David
    McLaughlin, Mark
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
12345